Indeed, all of the previous studies cited a focus on tumor biopsies, whereas, for a large proportion of mBC patients, especially those with HR+/HER2− mBC, metastases can only be localized in bones, leading to the technical failure of molecular analysis. Here, ERBB2 is linked to neoplasm.